Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **formin domain** (most often referring to the **formin homology (FH)** domains, especially FH2) is a protein domain present in all members of the formin protein family. Formins are important regulators of the actin and microtubule cytoskeleton. The FH2 domain, in particular, binds actin filament barbed ends and catalyzes nucleation and elongation of unbranched actin filaments[1][4][5][7]. Other domains (FH1, FH3, etc.) are involved in profilin binding, cellular localization, or regulatory functions. The term "formin domain" does not refer to a specific protein, enzyme, receptor, or therapeutic target, but rather to a conserved sequence found in a large family of proteins (formins). While formin proteins (such as DIAPH1, mDia1, or Bni1) can themselves be valid research or drug targets, the domain alone is not targetable and is generally not used in therapeutic contexts. Therefore, querying "formin domain" as a drug target is imprecise and may be incorrect for therapeutic targeting purposes[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Formin homology domain (FH domain (specifically, FH2 domain is most characteristic)).